Anti-SMAD2/SMAD3 Rabbit Monoclonal Antibody for WB, IP, ChIP, ELISA - Q15796 / P84022

Core Product Specifications and Parameters

Biological Background: SMAD2/SMAD3 Function and Localization

• SMAD2 (also known as JV18-1, hMAD-2, MADH2, MADR2) is an intracellular signal transducer and transcriptional modulator activated by TGF-beta and activin type 1 receptor kinases.
• Upon phosphorylation, SMAD2 forms a complex with SMAD4, translocates to the nucleus, and binds the TRE element in promoter regions of TGF-beta-responsive genes to regulate transcription. This includes promoting TGFB1-mediated odontoblastic differentiation (by similarity).
• May act as a tumor suppressor in colorectal carcinoma. Related references: PMID:8752209
• Predominantly cytoplasmic under basal conditions; translocates to the nucleus upon TGF-beta pathway activation.
• Expressed at high levels in skeletal muscle, endothelial cells, heart, and placenta.
• Contains zinc-binding domains and is subject to phosphorylation, acetylation, and ubiquitination, which regulate its activity and stability.

Experimental Guidance and Technical Tips

• The immunogen targets a conserved region (aa 198-298) shared between human SMAD2 and SMAD3, enabling dual recognition. Verify specificity for each isoform in your sample system using appropriate controls.
• For Western blotting, observe bands between 25–52 kDa due to post-translational modifications and potential isoform variation. Include phosphatase inhibitors to preserve phosphorylation status.
• In immunoprecipitation and ChIP assays, optimize crosslinking or native conditions based on the nuclear translocation dynamics of SMAD2/SMAD3 upon pathway stimulation.
• For ELISA, ensure antibody pairing compatibility and validate using recombinant SMAD2/SMAD3 protein or cell lysates with known TGF-beta activation status.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers and research labs with a streamlined channel to procure validated antibody pairs, optimized monoclonal/polyclonal antibodies, and bulk ancillary reagents for IVD development. With expertise in rare-target raw material sourcing, we support projects involving the TGF-beta/SMAD signaling axis—from early-stage feasibility to commercial scale—while maintaining rigorous supply consistency.